ACP-01
-
Hemostemix Plans to Revolutionize Stem Cell Therapy with Scalable Production and New Sales Goals
Hemostemix Inc. (TSXV: HEM | OTCQB: HMTXF | FSE: 2VF0) has developed an effective “stem cell therapy” for…
-
Thomas Smeenk provides an update on Hemostemix’s ACP-01 stem cell treatment for heart disease
Peter Clausi interviews Hemostemix Inc.’s (TSXV: HEM | OTCQB: HMTXF) Co-Founder, President and CEO Thomas Smeenk about an…
-
Hemostemix adds depth and strength to its scientific bench on the road to commercialization
Since we last covered Hemostemix where they released the promising results of their retrospective study of heart disease…
-
Hemostemix posts promising clinical trial results from heart failure and limb ischemia treatment
Heart failure (HF) is a growing epidemic in the United States, with an estimated 6 million people affected.…
-
Thomas Smeenk of Hemostemix talks about market reaction to successful litigation settlement
In this InvestorIntel interview with host Stephen Lautens, Hemostemix Inc.’s (TSXV: HEM | OTCQB: HMTXF) Co-Founder, President and…
-
Hemostemix’s stem cell therapy pursues ‘Your Fountain of Youth’
What’s a company worth to investors that could improve numerous medical conditions related to ischemia (lack of blood…
-
Thomas Smeenk on Hemostemix products for Your Fountain of Youth
In a recent InvestorIntel interview, Tracy Weslosky spoke with Thomas Smeenk, Co-Founder, President and CEO of Hemostemix Inc. (TSXV:…
-
Revolutionizing the way we treat lack of blood flow diseases by using stem cell therapy
Every year modern medicine makes new breakthroughs that continue to amaze. Today’s company has a breakthrough ‘stem cell…
-
Thomas Smeenk with an update on the FDA Phase II clinical trial program of the Hemostemix blood-derived, stem cell therapeutics product (ACP-01)
In a recent InvestorIntel interview, Peter Clausi speaks with Thomas Smeenk, Co-Founder, President and CEO of Hemostemix Inc. (TSXV:…
